Casdin Partners Files New Intent to Sell $6.0M in BioLife Solutions Stock
BLFS sits 34% above its 52-week low of $17.86 on elevated volume (2.9× avg).
Summary
Casdin Partners, a 10% shareholder, filed a new Form 144 to sell $6.0 million of BioLife Solutions stock, continuing a pattern of significant stake reduction.
Key Events · Ownership and Investor Activity · BLFS
-
New Intent to Sell
Casdin Partners Master Fund, L.P., a 10% shareholder, intends to sell 250,000 shares of common stock, valued at approximately $6.0 million.
-
Continuation of Selling Pattern
This filing follows a previous intent to sell $6.69 million (filed 2026-05-19) and actual sales of $6.795 million (300,000 shares) by Casdin Partners in the past three months.
-
Institutional Distribution
The ongoing sales by a major institutional investor could indicate a shift in their investment thesis or a need for liquidity, potentially creating selling pressure.
Analysis · BLFS · Industrial Applications And Services
Casdin Partners, a 10% shareholder, has filed another Form 144 indicating intent to sell $6.0 million worth of BioLife Solutions common stock. This follows a previous intent to sell $6.69 million and actual sales of $6.795 million in the past three months, signaling a continued reduction in their stake. This ongoing distribution by a major institutional investor could create an overhang on the stock.
At the time of this filing, BLFS was trading at $24.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $17.86 to $29.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.